Novartis says Phase II trials for lymphoma drug candidate shows overall response rate of 47% at 3 months

7 December 2015

Swiss pharma giant Novartis (NOVN: VX) said mid-stage trials for its therapy to treat non-Hodgkin lymphoma showed an overall response rate (ORR) at three months of 47% in patients with diffuse large B-cell lymphoma (DLBCL).

The results were presented at the 57th American Society of Hematology (ASH) annual meeting.

Lead investigator Dr Stephen Schuster, Associate Professor, division of hematology/oncology at the University of Pennsylvania, Abramson Cancer Center, said: "These data add to the growing body of clinical evidence on CTL019 and illustrate its potential benefit in the treatment of relapsed and refractory non-Hodgkin lymphoma, a disease with few effective options."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK